Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Chief Medical Officer | September 15, 2026 | September 15, 2026 |
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | CHIEF MEDICAL OFFICER | April 05, 2024 | April 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,771 |
Ending reported balance
After 2026-09-15 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 3,500 · Balance 36,218 Row 2 · 2026-09-15 · Exercise / conversion · Acquired 3,500 · Balance 39,718 Row 3 · 2026-09-15 · Sale · Disposed 2,384 · Balance 37,334 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.52 to $91.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Row 4 · 2026-09-15 · Sale · Disposed 3,150 · Balance 34,184 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.56 to $92.55, inclusive. Row 5 · 2026-09-15 · Sale · Disposed 1,366 · Balance 32,818 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.62 to $93.54, inclusive. Row 6 · 2026-09-15 · Sale · Disposed 100 · Balance 32,718 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.04 to $94.35, inclusive. Row 7 · 2026-09-15 · Sale · Disposed 947 · Balance 31,771 F6: These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.84 · Expires 2034-05-06 | Direct | 193,563 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 3,500 · Balance 193,563 F7: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. |
| Employee Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2034-07-14 | Direct | 164,992 |
Reported balance
After 2026-09-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-15 · Exercise / conversion · Disposed 3,500 · Balance 164,992 F8: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.52 to $91.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.56 to $92.55, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.62 to $93.54, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.04 to $94.35, inclusive.
F6: These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.
F7: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
F8: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
Tvardi Therapeutics, Inc.
Report date April 05, 2024 · Filed April 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,365 |
Reported balance
After 2024-04-05 transaction · row 1
1 source rowRow 1 · 2024-04-05 · Sale · Disposed 2,753 · Balance 53,365 F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 1,177 | $41.94 | $49,358.79 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · nonDerivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,018 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.75 to $42.28, inclusive. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,902 | $41.20 | $119,568.78 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,195 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.72 to $41.70, inclusive. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,921 | $40.11 | $117,158.68 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,097 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.64, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 22:24 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000020 · form4.xml · derivative · entry 6 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,492 Underlying: Common Stock · 3,500 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 22:24 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-26-000020 · form4.xml · derivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,063 Underlying: Common Stock · 3,500 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 22:24 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 936 | $32.78 | $30,686.01 |
DisclosureSEC source: 0000907654-26-000020 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,018 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.69 to $32.93, inclusive. Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 22:24 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 6,064 | $32.30 | $195,872.66 |
DisclosureSEC source: 0000907654-26-000020 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,954 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.68 to $32.67, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 22:24 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-26-000020 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 22:24 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-26-000020 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:40 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $34.39 | $0.00 |
DisclosureSEC source: 0000907654-26-000018 · form4.xml · derivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2036-01-22 F2 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:40 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000907654-26-000018 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,018 F1 · shares: The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day). Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:26 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000004 · form4.xml · derivative · entry 6 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,992 Underlying: Common Stock · 3,500 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:26 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-26-000004 · form4.xml · derivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,563 Underlying: Common Stock · 3,500 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:26 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 2,619 | $32.24 | $84,428.70 |
DisclosureSEC source: 0000907654-26-000004 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,518 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.86 to $32.71, inclusive. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:26 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 4,381 | $31.56 | $138,275.75 |
DisclosureSEC source: 0000907654-26-000004 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,137 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.86 to $31.85, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:26 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-26-000004 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:26 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-26-000004 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 22:38 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Warrant (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-25-000023 · form4.xml · derivative · entry 8 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,492 Underlying: Common Stock · 3,500 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 22:38 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-25-000023 · form4.xml · derivative · entry 7 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 225,063 Underlying: Common Stock · 3,500 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 22:38 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 3,080 | $31.58 | $97,263.32 |
DisclosureSEC source: 0000907654-25-000023 · form4.xml · nonDerivative · entry 6 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,518 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $32.00, inclusive. Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 22:38 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 1,492 | $30.70 | $45,806.04 |
DisclosureSEC source: 0000907654-25-000023 · form4.xml · nonDerivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,598 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $31.18, inclusive. Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 22:38 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 1,787 | $29.62 | $52,934.51 |
DisclosureSEC source: 0000907654-25-000023 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,090 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.15 to $30.13, inclusive. Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 22:38 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 641 | $28.53 | $18,289.14 |
DisclosureSEC source: 0000907654-25-000023 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,877 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.14 to $29.12, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5) and (6) to this Form 4. Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 22:38 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-25-000023 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 22:38 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-25-000023 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 191 shares acquired under the Oruka stock purchase plan on December 8, 2024, 661 shares acquired under the Oruka stock purchase plan on June 8, 2025 and 666 shares acquired under the Oruka stock purchase plan on December 8, 2025. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:43 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantEmployee Stock Option (right to buy) · Derivative | 162,500 | $0.00 Strike: $12.50 | $0.00 |
DisclosureSEC source: 0001062993-25-001088 · form4.xml · derivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2035-01-21 F1 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 20:22 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,753 | $0.83 | $2,284.99 |
DisclosureSEC source: 0001415889-24-010570 · form4-04092024_080455.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,365 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 21:13 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,293 | $0.89 | $2,930.77 |
DisclosureSEC source: 0001415889-24-006265 · form4-03042024_090307.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,118 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:30 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002522 · form4-02052024_090202.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,181 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 20:07 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,723 | $3.51 | $9,557.73 |
DisclosureSEC source: 0001209191-23-039882 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,681 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 21:13 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,481 | $4.91 | $12,181.71 |
DisclosureSEC source: 0001209191-23-023606 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,404 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.82 to $4.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:43 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 6,221 | $9.71 | $60,405.91 |
DisclosureSEC source: 0001209191-23-016788 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,885 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.60 to $9.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:37 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 81,000 | $0.00 Strike: $10.06 | $0.00 |
DisclosureSEC source: 0001209191-23-015566 · doc4.xml · derivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires 2033-03-01 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 1, 2023, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:27 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,265 | $10.20 | $23,103.00 |
DisclosureSEC source: 0001209191-23-010627 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,106 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person. Read SEC document |
| February 08, 2023 Filed Feb 12, 2024 22:13 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 7,770 | $0.53 | $4,118.10 |
DisclosureSEC source: 0001415889-24-003400 · form4-02122024_100214.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,411 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:18 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,265 | $10.81 | $24,484.65 |
DisclosureSEC source: 0001209191-23-004013 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,371 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 21:32 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,265 | $10.18 | $23,057.70 |
DisclosureSEC source: 0001209191-23-000232 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,636 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 21:53 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,992 | $11.27 | $33,719.84 |
DisclosureSEC source: 0001209191-22-062629 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,901 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on December 21, 2021, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:50 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 1,642 | $11.91 | $19,556.22 |
DisclosureSEC source: 0001209191-22-023248 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,893 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on April 1, 2021, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:14 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-22-013983 · doc4.xml · derivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-02-25 F3 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:14 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 1,972 | $10.29 | $20,291.88 |
DisclosureSEC source: 0001209191-22-013983 · doc4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,535 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:14 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013983 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,507 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 22:29 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 12,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070808 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,507 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest as to (i) 50% on December 15, 2022; and (ii) 50% on June 15, 2023, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:55 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 1,000 | $17.15 | $17,150.00 |
DisclosureSEC source: 0001209191-21-062727 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,900 F1 · kind: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2021. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 22:34 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 1,000 | $15.00 | $15,000.00 |
DisclosureSEC source: 0001209191-21-061953 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,900 F1 · kind: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2021. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 22:06 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,110 | $14.20 | $29,962.00 |
DisclosureSEC source: 0001209191-21-054301 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,900 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 24, 2021 Filed Aug 26, 2021 22:16 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 6,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-053536 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,010 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on August 24, 2021. The vested shares represents the first of two possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 21:05 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,000 | $27.63 | $82,890.00 |
DisclosureSEC source: 0001209191-21-028141 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,610 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on November 15, 2019 and amended on August 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.41 - $28.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.